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e appreciate the perspectives offered by Drs. Terkelsen and
ielsen regarding the optimal approach to achieving timely reper-
usion for acute ST-segment elevation myocardial infarction
STEMI). In our review (1), we strongly favored the view that
rimary percutaneous coronary intervention (PCI) represents the
est modality of reperfusion in STEMI patients and, in a perfect
orld with no resource limitations or cost restraints, would be the
reatment of choice for all STEMI patients. However, we at-
empted to address the “real-world” challenges that exist within the
.S., where 1) fully one-third of all STEMI patients currently
eceive no reperfusion (fibrinolytic or mechanical) acutely; 2) theajority of STEMI patients (60% to 70%) present initially to
on-PCI-capable hospitals, which creates inevitable transport
elays to PCI-capable facilities that are frequently beyond the
ontrol of emergency medicine physicians and cardiologists; 3) the
roup of “transfer-in” STEMI patients to PCI-capable hospitals
arely achieve door-to-balloon (DTB) times of90 min (only 8%,
ccording to the Chakrabarti et al. [2] recent analysis of the
ational Registry of Myocardial Infarction); and 4) among
TEMI patients who present within 3 h of initial STEMI
ymptom-onset, there is no clear advantage of a mechanical
eperfusion strategy over a pharmacologic reperfusion strategy,
hich form the basis for the current American College of
ardiology/American Heart Association clinical practice guideline
ecommendations that, in such patients, either reperfusion ap-
roach is considered a Class IA recommendation (3).
Our goal in this review (1) was to address primarily the
anagement issues confronting acute STEMI management in
atients presenting to community hospitals without on-site PCI
apability. In such settings, both emergency medicine physicians
nd cardiologists must quickly decide whether urgent transport to
PCI-capable hospital can likely achieve prompt reperfusion with
DTB 90 min or, alternatively, whether the use of a bolus
brinolytic agent (in a patient without evident contraindications)
ould be a more appropriate reperfusion strategy. If, in fact, 92%
f all such STEMI patients who require urgent transfer for
rimary PCI do not achieve DTB times 90 min, it seems
easonable to consider a pharmacologic reperfusion approach,
ecause there is an almost a 40% relative increase in 30-day
ortality among patients in whom reperfusion is delayed beyond
20 min.
Although both regional and national initiatives are presently
nderway within the U.S. to streamline and expedite STEMI
anagement by using enhanced, field-based electrocardiogram
iagnosis to bypass community hospitals without on-site PCI
apability and instead direct such patients de novo to PCI-capable
ospitals, these efforts are not yet widely developed in many
ommunities and inherently conflict with existing Emergency
edical Service infrastructure nationwide, which continues to
spouse the transport of myocardial infarction patients to the
losest hospital. Accordingly, unlike most of European countries,
here there is more highly coordinated and expedited STEMI
ransport to PCI-capable facilities, the logistical limitations that
ontinue to exist within the U.S. regarding triage and transport of
TEMI patients represent formidable barriers to expanding and
chieving a more broad-based system of primary PCI for all
TEMI patients.
Therefore, we believe our review highlights the need for both
echanical and pharmacologic reperfusion, as dictated by local
esource availability, as the best overall approach to expediting
imely reperfusion in patients who present with STEMI to either
ural or urban hospitals where differential systems and processes of
are may influence clinical decision-making.
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rterial Microvessels: An Early
r Late Sign of Atherosclerosis?
ypoxia is a strong stimulus for the induction of angiogenesis. In an
legant series of experiments, including in vivo labeling of hypoxic
issues, Sluimer et al. (1) have demonstrated that hypoxia in advanced
therosclerotic plaques colocalized with the expression of hypoxia-
nduced transcription factors (i.e., HIF1, HIF2), growth factors
i.e., vascular endothelial growth factor), and glucose transporters (i.e.,
LUT1, GLUT3) and that all these microenvironmental changes
ere accompanied by neovascularization—the number of microvessels
er mm2 intima area was significantly greater in advanced than in
arly atherosclerotic lesions.
We have previously shown that 2 distinctive angiogenic events
ccur during atherosclerosis in humans (2). In addition to ectopic
laque neovascularization, we found a hyperplastic network of vasa
asorum in the arterial adventitia in early lesions of patients with
ctive, symptomatic disease. However, the arterial adventitia is a
hysiologically vascularized compartment of the arterial wall and is
ot expected to harbor a hypoxic microenvironment. Studies based
n swine models of hypercholesterolemia showed that adventitial
eovascularization is not exclusively related to plaque formation;
hose animals presented with the highest vasa vasorum count but
ithout any arterial wall thickening (3). The authors suggested
hat the main stimulus to vessel wall neovascularization might not
e local hypoxia but could rather be related to the increased
xidative stress.
However, Sluimer et al. (1) showed that metabolically active
acrophages may contribute to tissue hypoxia by oxygen exhaustion
4) and that this mechanism could also contribute to hyperplasia of
asa vasorum in the arterial adventitia. Because contrast-enhanced
ranscutaneous ultrasound is a bedside procedure that can be used to
isualize both plaque (5) and adventitial microvessels (6), the 2
ompartments might be accessible for the diagnosis of early and late
tages of preclinical atherosclerosis. A common pathogenic mecha-
ism might eventually be targeted therapeutically.
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n their letter, Dr. Biedermann and colleagues point to the
xistence of distinct angiogenic events in the intima and adventitia
n human atherosclerosis. They also suggest that adventitial an-
iogenesis might not be driven by local hypoxia, whereas the
ntima is hypoxic and may drive intimal angiogenesis, as we have
hown in our recent paper (1).
In that study, we were not able to analyze the existence of
ypoxia in the adventitia because our analysis was restricted to
arotid endarterectomy specimen that only contained the intima
nd small parts of the media. It is known that the adventitia does
ontain macrophages, which does increase the quest for oxygen,
nd adventitial microvessels are present. As suggested recently, one
eason for adventitial hypoxia might be insufficient perfusion,
ecause the adventitial vessels are very thin walled (J.C. Sluimer et
l., unpublished data, March 2008) and may collapse at least in
art during the cardiac cycle (2). The true value of this suggestion,
owever, needs to be determined by the actual quantification of
dventitial microvessel flow during the cardiac cycle.
Plaque macrophage hypoxic stress is indeed suggested to be a
trong driver of plaque angiogenesis. Although adventitial and plaque
ngiogenesis may have another driving stimulus, there is a close
onnection between plaque and adventitial microvessels, because the
ast majority of plaque vessels seem to sprout from adventitial
icrovessels that penetrate through the media, as demonstrated by
irmani et al. (3). This close anatomic connection between adventitial
nd plaque microvessels might therefore also stimulate angiogenesis in
he adventitia, albeit indirectly. We agree with Dr. Biedermann and
olleagues that this does not implicate that the reverse—increased
dventitial angiogenesis causes increased plaque angiogenesis—is also
rue. We do support the call and need for adequate visualization
echnologies able to quantify plaque and adventitial angiogenesis. In
